CytoDyn to Initiate 8 Pre-Clinical Animal Studies with Leronlimab (PRO 140) for Melanoma, Pancreatic, Breast, Prostate, Colon, Lung, Liver, and Stomach Cancer at an Estimated Cost of $1.5 million, which Could Lead to 8 Phase 2 Clinical Studies

VANCOUVER, Washington, Feb. 19, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody, leronlimab (PRO 140), for multiple therapeutic indications, announced…

Continue Reading

Premier Biomedical Signs Agreement With CBD HEMP Distributing Company to Distribute Premier’s Topical Pain Relief Products In Four Northeastern States

Premier Biomedical Signs Agreement With CBD HEMP Distributing Company to Distribute Premier’s Topical Pain Relief Products In Four Northeastern States JACKSON CENTER, PA / ACCESSWIRE / December 6, 2018 / Premier Biomedical, Inc (OTC: BIEI)…

Continue Reading
Close Menu